Is Vaxart Inc (VXRT) Stock a Good Buy on Thursday?

Thursday, July 2, 2020 2:59 PM | InvestorsObserver Analysts

Vaxart Inc (VXRT) stock has gained 17.57% over the past week and gets a Neutral rating from InvestorsObserver's Sentiment Indicator.

Sentiment Score - ,neutral
Vaxart Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on VXRT!

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.

Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.

InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.

The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With VXRT Stock Today?

Vaxart Inc (VXRT) stock is down -8% while the S&P 500 has risen 0.92% as of 2:59 PM on Thursday, Jul 2. VXRT is lower by -$0.64 from the previous closing price of $8.00 on volume of 15,116,082 shares. Over the past year the S&P 500 has gained 5.77% while VXRT has risen 966.67%. VXRT lost -$0.86 per share in the over the last 12 months.

To see the top 5 stocks in the Biotechnology industry click here.

More About Vaxart Inc

Vaxart Inc is a biopharmaceutical company. It is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The company has three product candidates which are; Influenza, Norovirus and RSV Vaccine, an oral fusion protein inhibitor for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in for condyloma caused by human papillomavirus.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 65% with annual

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

You May Also Like

Related Articles

Alterity Therapeutics Ltd (ATHE) Stock: What Does the Chart Say?

Medtronic (MDT) Announces First InterStim Implant

Sector Update: Health Care

Related Companies